[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20000323A1 - VITRONECTIN RECEPTOR ANTAGONISTS - Google Patents

VITRONECTIN RECEPTOR ANTAGONISTS

Info

Publication number
PE20000323A1
PE20000323A1 PE1999000188A PE00018899A PE20000323A1 PE 20000323 A1 PE20000323 A1 PE 20000323A1 PE 1999000188 A PE1999000188 A PE 1999000188A PE 00018899 A PE00018899 A PE 00018899A PE 20000323 A1 PE20000323 A1 PE 20000323A1
Authority
PE
Peru
Prior art keywords
alkyl
het
compound
vitronectin receptor
chrg
Prior art date
Application number
PE1999000188A
Other languages
Spanish (es)
Inventor
William H Miller
Dirk Heerding
James M Samanen
John G Gleason
Irene N Uzinskas
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20000323A1 publication Critical patent/PE20000323A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R* ES -X-CH(-R1)-CH2-CO2H, -CH2-N(-R1)-CH2-CO2H, -Cl; X E Y SON CR`R', NR', S; A ES H, HALO, ORg, -SRg, CN, NRgRk, -NO2, -CF3, ENTRE OTROS; R1 ES -ALQUIL C0-C6(HET), -(ALQUIL C0-C6)Ar, ENTRE OTROS; R2 ES UN GRUPO DE FORMULA a, b, ENTRE OTROS; W ES -(CHRg)a-U-(CHRg)b-; U ESTA AUSENTE O ES CO, C(Rg)2, C(=CRg2), S(O)k, ENTRE OTROS; G ES NRe, S, O; Rg ES H, ALQUILO C1-C6, HET(ALQUILO C0-C6), ENTRE OTROS; Rk ES Rg, -CORg, -COORf; Ri ES H, ALQUILO C1-C6, HET(ALQUILO C0-C6), ENTRE OTROS; Rf ES H, ALQUILO C1-C6, Ar(ALQUILO C0-C6); Re ES H, ALQUILO C1-C6, Ar(ALQUILO C1-C6); Rb Y Rc SON H, ALQUILO C1-C6, Ar(ALQUILO C0-C6), ENTRE OTROS; UNO DE Q1, Q2, Q3, Q4 ES N Y EL RESTO ES CRy; R' ES H, ALQUILO C1-C6, Ar-ALQUILO C0-C6; R'' ES R', COR', COOR'; RY ES H, HALO, CRg, SRg, CN, ENTRE OTROS; a, b, k, r Y s SON 0-2; u Y v SON 0-1. UN COMPUESTO PREFERIDO ES ACIDO (+/-)-3-FENIL-4-[4-[3-(PIRIDIN-2-IL)AMINO-1-PROPIL-OXI]FENIL]BUTANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE VITRONECTINA Ovß3 Y Ovß5 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA OSTEOPOROSIS, INFLAMACION, CANCER, TRASTORNOS CARDIOVASCULARES TALES COMO ATEROSCLEROSIS Y RESTENOSISREFERS TO A COMPOUND OF FORMULA I WHERE R * IS -X-CH (-R1) -CH2-CO2H, -CH2-N (-R1) -CH2-CO2H, -Cl; X AND Y ARE CR`R ', NR', S; A IS H, HALO, ORg, -SRg, CN, NRgRk, -NO2, -CF3, AMONG OTHERS; R1 IS -C0-C6 ALKYL (HET), - (C0-C6 ALKYL) Ar, AMONG OTHERS; R2 IS A GROUP OF FORMULA a, b, AMONG OTHERS; W ES - (CHRg) a-U- (CHRg) b-; U IS ABSENT OR IS CO, C (Rg) 2, C (= CRg2), S (O) k, AMONG OTHERS; G IS NRe, S, O; Rg IS H, C1-C6 ALKYL, HET (C0-C6 ALKYL), AMONG OTHERS; Rk IS Rg, -CORg, -COORf; Ri IS H, C1-C6 ALKYL, HET (C0-C6 ALKYL), AMONG OTHERS; Rf IS H, C1-C6 ALKYL, Ar (C0-C6 ALKYL); Re IS H, C1-C6 ALKYL, Ar (C1-C6 ALKYL); Rb AND Rc ARE H, C1-C6 ALKYL, Ar (C0-C6 ALKYL), AMONG OTHERS; ONE OF Q1, Q2, Q3, Q4 IS N AND THE REST IS CRy; R 'IS H, C1-C6 ALKYL, Ar-C0-C6 ALKYL; R '' IS R ', COR', COOR '; RY IS H, HALO, CRg, SRg, CN, AMONG OTHERS; a, b, k, r AND s ARE 0-2; u AND v ARE 0-1. A PREFERRED COMPOUND IS (+/-) - 3-PHENYL-4- [4- [3- (PYRIDIN-2-IL) AMINO-1-PROPYL-OXY] PHENYL] BUTANOIC ACID, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. COMPOUND I IS AN ANTAGONIST OF THE Ovß3 AND Ovß5 VITRONECTIN RECEPTOR AND MAY BE USEFUL FOR THE TREATMENT OF OSTEOPOROSIS, INFLAMMATION, CANCER, CARDIOVASCULAR DISORDERS SUCH AS ATHEROSCLEROSIS AND RESTENOSIS

PE1999000188A 1998-03-10 1999-03-10 VITRONECTIN RECEPTOR ANTAGONISTS PE20000323A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
PE20000323A1 true PE20000323A1 (en) 2000-05-24

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000188A PE20000323A1 (en) 1998-03-10 1999-03-10 VITRONECTIN RECEPTOR ANTAGONISTS

Country Status (24)

Country Link
EP (1) EP1061921A4 (en)
JP (1) JP2002506033A (en)
KR (1) KR20010041812A (en)
CN (1) CN1299282A (en)
AP (1) AP2000001898A0 (en)
AR (1) AR015241A1 (en)
AU (1) AU758498B2 (en)
BG (1) BG104824A (en)
BR (1) BR9908636A (en)
CA (1) CA2323208A1 (en)
CO (1) CO5080762A1 (en)
DZ (1) DZ2741A1 (en)
EA (1) EA200000921A1 (en)
HU (1) HUP0101143A3 (en)
ID (1) ID26223A (en)
IL (1) IL138245A0 (en)
NO (1) NO20004503L (en)
OA (1) OA12189A (en)
PE (1) PE20000323A1 (en)
PL (1) PL342881A1 (en)
SK (1) SK13292000A3 (en)
TR (1) TR200002625T2 (en)
UY (2) UY25421A1 (en)
WO (1) WO1999045927A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (en) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitors of the integrin alphavbeta¶3¶
DE19939981A1 (en) * 1999-08-24 2001-03-01 Merck Patent Gmbh New inhibitors of the integrin alphavß3
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
FR2808798A1 (en) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20070275956A1 (en) * 2003-10-14 2007-11-29 Lohray Braj B Novel Heterocyclic Compounds
AU2005219737B2 (en) * 2004-03-05 2009-11-19 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080004554A (en) 2005-04-20 2008-01-09 얀센 파마슈티카 엔.브이. Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls
AU2014312756B2 (en) * 2013-08-29 2018-11-22 Kyoto Pharmaceutical Industries, Ltd. Novel aromatic compound and use thereof
LT3929196T (en) 2013-09-24 2023-09-25 Fujifilm Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502708A (en) * 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
US6159964A (en) * 1995-12-29 2000-12-12 Smithkline Beecham Corporation Vitronectin receptor antagonists

Also Published As

Publication number Publication date
AU758498B2 (en) 2003-03-20
UY25519A1 (en) 1999-12-13
JP2002506033A (en) 2002-02-26
BR9908636A (en) 2002-01-08
CN1299282A (en) 2001-06-13
OA12189A (en) 2006-05-09
EP1061921A1 (en) 2000-12-27
PL342881A1 (en) 2001-07-16
CO5080762A1 (en) 2001-09-25
AP2000001898A0 (en) 2000-09-30
BG104824A (en) 2001-05-31
HUP0101143A2 (en) 2001-08-28
DZ2741A1 (en) 2003-09-08
SK13292000A3 (en) 2001-06-11
AR015241A1 (en) 2001-04-18
TR200002625T2 (en) 2000-12-21
IL138245A0 (en) 2001-10-31
EP1061921A4 (en) 2005-03-30
HUP0101143A3 (en) 2002-12-28
WO1999045927A1 (en) 1999-09-16
NO20004503D0 (en) 2000-09-08
ID26223A (en) 2000-12-07
KR20010041812A (en) 2001-05-25
EA200000921A1 (en) 2001-04-23
UY25421A1 (en) 2001-07-31
NO20004503L (en) 2000-10-10
CA2323208A1 (en) 1999-09-16
AU2903399A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
PE20000323A1 (en) VITRONECTIN RECEPTOR ANTAGONISTS
ES2427445T3 (en) Quinazoline derivatives to inhibit the growth of cancer cells and method for preparing them
ES2330552T3 (en) DERIVATIVES OF PYRIMIDIN-5-ONA AS INHIBITORS OF LDL-PLA2.
AU2004257639B2 (en) Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
AU711438B2 (en) 7-amino-1H-indol derivatives
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
KR960003604B1 (en) Benzimidazoline-2-oxo-1-carboxylic acid derivatives
AU2003301853B2 (en) Indoles useful in the treatment of androgen- receptor related diseases
HUP0401855A2 (en) Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-ir), process for their preparation, their use and pharmaceutical compositions containing them
ATE277889T1 (en) AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA
TWI289558B (en) New compounds
WO2001072708A3 (en) OXINDOLE INHIBITORS OF FACTOR Xa
DE60126339D1 (en) WATER-FREE COSMETIC COMPOSITION
DE60014394D1 (en) AMINOBENZOPHENONE AS INHIBITORS OF IL-1BETA AND TNF-ALPHA
AP2003002810A0 (en) 1,4-Disubstituted piperazine derivatives useful as uro-selective a, - adrenoceptor blockers
WO2005007633A1 (en) Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
PL169764B1 (en) Herbicide and method of killing weeds
HU208973B (en) Herbicide preparatives containing puyridine derivatives
PE20010649A1 (en) ANTRANYLAMIDE DERIVATIVES OF 1,4-DI-SUBSTITUTED PIPERIDINES AS MUSCARINAL ANTAGONISTS
EA200001009A1 (en) PYRIDINE DERIVATIVES INHIBITING PHOSPHODYESTERASE IV
PE20021154A1 (en) 4-AMINOPYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEPTOR
MX2007005566A (en) Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases.
PE20010582A1 (en) ANTAGONISTS OF VITRONECTIN RECEPTORS
MY123373A (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
US7795280B2 (en) Indoles useful in the treatment of androgen-receptor related diseases

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed